Digital eMPower program reduces anxiety and depression in adults with chronic conditions, with self-directed delivery matching human-supported outcomes
核心洞察
A fully remote, three-arm randomized controlled trial across 13 countries (n=825) found the eMPower digital program significantly reduced anxiety (搜索) and depression (搜索) symptoms compared with usual care at 12 weeks.
The human-supported arm improved HADS total score by 2.9 points (95% CI 2.0–3.8; p<0.001), with the self-directed arm showing a comparable 2.6-point improvement (95% CI 1.8–3.5; p<0.001).
Exploratory analyses found no significant difference between self-directed and human-supported delivery, suggesting a scalable "digital first" model may be feasible for broad implementation.
A multicomponent digital intervention combining guided movement, breathwork and meditation, coping-skills training, and disease education significantly reduced anxiety (搜索) and depression (搜索) symptoms in adults living with chronic medical conditions, according to a three-arm randomized controlled trial published August 20, 2026 in PLOS Medicine. The eMPower trial, led by Puneeta Tandon of the University of Alberta, Canada, and colleagues, enrolled 825 adults across 13 countries and found that both a human-supported and a fully self-directed version of the program produced clinically meaningful improvements compared with usual care.
The study addresses a substantial unmet need: anxiety (搜索), depression (搜索), and fatigue (搜索) affect more than 50% of adults across a range of chronic medical conditions, leading to reductions in quality of life. Access to effective symptom management support is limited by mobility barriers, geography, cost, and shortages of trained clinicians, creating an urgent need for scalable, low-resource approaches.
Trial Design and Population
The eMPower trial was a three-arm, parallel-group, open-label randomized controlled trial conducted from February 2023 to December 2024, with online recruitment and delivery across 13 countries. A total of 825 adults (≥18 years) with self-reported chronic medical conditions and internet access were allocated by computer-generated stratified block randomization (1:1:1) to a waitlist control group (n=274), a self-directed eMPower program (n=275), or eMPower plus human support consisting of weekly telephone check-ins (≤15 minutes) from trained nonclinicians (n=276).
The program integrated expert-led breathwork, meditation, and movement videos (including chair exercise, yoga, and Tai-chi) at multiple difficulty levels, a psychologist-led coping-skills curriculum based on Acceptance and Commitment Therapy (ACT), and disease-specific education videos delivered by clinicians. The intervention was co-designed with patients and informed by the capability, opportunity, motivation-behavior (COM-B) model, incorporating 22 behavior change techniques to support adherence.
The sample had a mean age of 55.6 ± 12.7 years, with 24% (n=198) over age 65. Participants were predominantly female (84%) and white (88.5%), with 70% reporting post-secondary education. The most common conditions were Primary Biliary Cholangitis (搜索) (PBC) (22.3%), chronic digestive diseases (15.5%), and post-transplant status (13.5%). Retention was strong for a fully online study, with 84.2% (n=695) completing 12-week assessments.
Primary Outcome
The primary outcome was change in Hospital Anxiety (搜索) and Depression (搜索) Scale (HADS) total score from baseline to 12 weeks in the eMPower + human support arm compared with control, adjusted for baseline score, chronic condition type, age, and sex. In the prespecified primary comparison, eMPower + human support improved HADS total score by 2.9 points (95% CI [2.0, 3.8]; p < 0.001), representing a 20% relative improvement. Both anxiety and depression subscales improved significantly, by 1.5 points and 1.4 points respectively (both p < 0.001).
The lower bound of the confidence interval exceeded the established minimum clinically important difference (MCID) of 1.5 to 1.7 points, and the effect was comparable to antidepressant trials in chronic disease (standardized mean difference ~0.3) and structured psychotherapy.
Secondary Outcomes and Exploratory Analyses
Participants in the eMPower + human support arm showed improvements across all secondary outcomes compared with control. After Hochberg correction for multiplicity, all six prespecified secondary outcomes remained statistically significant. Fatigue (搜索) showed the largest between-group difference, with an MFIS total score improvement of 8.4 points (95% CI [6.6, 10.4]; 19% relative improvement; p < 0.001), surpassing the MCID of 4.0 points. Mental health-related quality of life (SF-12 MCS) improved by 3.0 points (95% CI [1.8, 4.2]; p < 0.001).
In prespecified exploratory analyses, the self-directed eMPower arm also significantly improved HADS total score compared with control (mean difference 2.6 points; 95% CI [1.8, 3.5]; p < 0.001). Critically, no statistically significant differences were observed between the two intervention arms for any primary or secondary outcome (all p > 0.05).
"What was surprising was that, in an exploratory analysis, we did not find a significant difference between the fully self-directed program and the program with brief weekly check-ins from a trained team member," said corresponding author Dr. Puneeta Tandon. "This does not prove that the two approaches are equal, but it suggests that a program like this may be able to reach far more people without requiring one-to-one support for everyone. Support could then be focused on those who need it most."
Clinical Significance and Limitations
The authors note that the trial was powered for the primary comparison of eMPower + human support versus control, so the absence of a statistically significant difference between arms should not be interpreted as evidence of equivalence. Several trial-specific factors may explain the lack of a support effect, including the requirement for controlled psychiatric conditions and the brief, nonclinician-delivered, uniformly assigned nature of the support.
"Taken together, the eMPower clinical trial provides robust evidence that a fully digital, multicomponent intervention reduced anxiety (搜索) and depression (搜索) symptoms and was associated with improvements in fatigue (搜索), and quality of life across a range of chronic disease populations," the authors state. "Rather than developing separate digital programs for each condition, a single cross-condition approach with tailoring for disease-specific education is effective in addressing shared symptoms."
Key limitations include the use of a waitlist control design, which does not control for nonspecific intervention effects; reliance on self-reported diagnoses for most participants; the 12-week follow-up period; and a predominantly female, white, and highly educated sample, which may limit generalizability. The geographic concentration of participants in Canada (81.8%) may also introduce selection bias.
"As clinicians, we are good at treating organ-specific problems, but the whole-person burden of chronic illness — the anxiety (搜索), low mood and exhaustion — that is often where patients have fewer practical options," Dr. Tandon added. "While these skills don't replace medication or mental health care when those are needed, they do give people a practical place to start at home."
No intervention-related adverse events were reported in any arm. The trial was registered on ClinicalTrials.gov (NCT05786482) and funded by the Canadian Institutes of Health Research (CIHR), Mitacs, and TRIANGLE.